Letters
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. 1. Fernandez-Faith E, McDonnell J. Cutaneous sarcoidosis: differential diagnosis. Clin Dermatol. 2007;25(3):276-287. 2. Tchernev G, Patterson JW, Nenoff P, Horn LC. Sarcoidosis of the skin—a dermatological puzzle: important differential diagnostic aspects and guidelines for clinical and histopathological recognition. J Eur Acad Dermatol Venereol. 2010;24(2):125-137.
Lines Omitted From Table: In the Original Investigation entitled “Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013” published in the July 28, 2015, issue of JAMA,1 the last 2 rows of Table 2 (Expired and Others for 2007-2013) were inadvertently omitted. This article was corrected online. 1. Krumholz HM, Nuti SV, Downing NS, et al. Mortality, hospitalizations, and expenditures for the Medicare population aged 65 years or older, 1999-2013. JAMA. 2015;314(4):355-365.
3. Souza ES, Rocha Bde O, Batista Eda S, Oliveira RF, Farre L, Bittencourt AL. T-cell-predominant lymphoid hyperplasia in a tattoo. An Bras Dermatol. 2014; 89(6):1019-1021. 4. Weyers W, Metze D. Histopathology of drug eruptions—general criteria, common patterns, and differential diagnosis. Dermatol Pract Concept. 2011;1(1): 33-47.
Guidelines for Letters
Incorrect Values Reported: In the Original Investigation entitled “Cannabinoids for Medical Use: A Systematic Review and Meta-analysis” published in the June 23/30, 2015, issue of JAMA,1 the value for the average reduction in the Ashworth spasticity scale should have been reported as “weighted mean difference, −0.12 (95% CI, −0.24 to 0.01); 5 trials.” This article was corrected online.
Letters discussing a recent JAMA article should be submitted within 4 weeks of the article's publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jama.com/public /InstructionsForAuthors.aspx. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the JAMA online submission and review system at http: //manuscripts.jama.com. For technical assistance, please contact [email protected].
1. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473.
Section Editor: Jody W. Zylke, MD, Deputy Editor.
5. Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25 (2):72-78. 6. Toulemonde A, Quereux G, Dréno B. Sarcoidosis granuloma on a tattoo induced by interferon alpha [in French]. Ann Dermatol Venereol. 2004; 131(1 pt 1):49-51.
CORRECTION Incorrect Study Name: In the Review Article entitled “Stroke Prevention in Atrial Fibrillation: A Systematic Review” in the May 19, 2015, issue of JAMA,1 the ARISTOLE trial was incorrectly expanded. It should have read “Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation.” This article was corrected online. 1. Lip GYH, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA. 2015;313(19):1950-1962.
jama.com
(Reprinted) JAMA August 25, 2015 Volume 314, Number 8
Copyright 2015 American Medical Association. All rights reserved.
Downloaded From: http://jama.jamanetwork.com/pdfaccess.ashx?url=/data/journals/jama/934323/ by a Columbia University User on 06/22/2017
837
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. 1. Fernandez-Faith E, McDonnell J. Cutaneous sarcoidosis: differential diagnosis. Clin Dermatol. 2007;25(3):276-287. 2. Tchernev G, Patterson JW, Nenoff P, Horn LC. Sarcoidosis of the skin—a dermatological puzzle: important differential diagnostic aspects and guidelines for clinical and histopathological recognition. J Eur Acad Dermatol Venereol. 2010;24(2):125-137.
Lines Omitted From Table: In the Original Investigation entitled “Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013” published in the July 28, 2015, issue of JAMA,1 the last 2 rows of Table 2 (Expired and Others for 2007-2013) were inadvertently omitted. This article was corrected online. 1. Krumholz HM, Nuti SV, Downing NS, et al. Mortality, hospitalizations, and expenditures for the Medicare population aged 65 years or older, 1999-2013. JAMA. 2015;314(4):355-365.
3. Souza ES, Rocha Bde O, Batista Eda S, Oliveira RF, Farre L, Bittencourt AL. T-cell-predominant lymphoid hyperplasia in a tattoo. An Bras Dermatol. 2014; 89(6):1019-1021. 4. Weyers W, Metze D. Histopathology of drug eruptions—general criteria, common patterns, and differential diagnosis. Dermatol Pract Concept. 2011;1(1): 33-47.
Guidelines for Letters
Incorrect Values Reported: In the Original Investigation entitled “Cannabinoids for Medical Use: A Systematic Review and Meta-analysis” published in the June 23/30, 2015, issue of JAMA,1 the value for the average reduction in the Ashworth spasticity scale should have been reported as “weighted mean difference, −0.12 (95% CI, −0.24 to 0.01); 5 trials.” This article was corrected online.
Letters discussing a recent JAMA article should be submitted within 4 weeks of the article's publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jama.com/public /InstructionsForAuthors.aspx. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the JAMA online submission and review system at http: //manuscripts.jama.com. For technical assistance, please contact [email protected].
1. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473.
Section Editor: Jody W. Zylke, MD, Deputy Editor.
5. Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25 (2):72-78. 6. Toulemonde A, Quereux G, Dréno B. Sarcoidosis granuloma on a tattoo induced by interferon alpha [in French]. Ann Dermatol Venereol. 2004; 131(1 pt 1):49-51.
CORRECTION Incorrect Study Name: In the Review Article entitled “Stroke Prevention in Atrial Fibrillation: A Systematic Review” in the May 19, 2015, issue of JAMA,1 the ARISTOLE trial was incorrectly expanded. It should have read “Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation.” This article was corrected online. 1. Lip GYH, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA. 2015;313(19):1950-1962.
jama.com
(Reprinted) JAMA August 25, 2015 Volume 314, Number 8
Copyright 2015 American Medical Association. All rights reserved.
Downloaded From: http://jama.jamanetwork.com/pdfaccess.ashx?url=/data/journals/jama/934323/ by a Columbia University User on 06/22/2017
837
